PARP1 and Miyoshi myopathy: Botrugno et al. (2019) also identified additional synthetic lethal approaches, beyond the PARP1, where the combination of DNA damaging agents, commonly used in the clinic to treat MM, could be associated with novel interventions to prevent cells from repairing DNA and hence trigger apoptosis [41].